DNLI250117P20000
- 1.80
- 0.000.00%
Denali Therapeutics Newsroom
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
Denali Therapeutics (DNLI) Receives a Buy From TD Cowen
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $30
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $41
Denali Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $24 to $87
Denali Therapeutics Analyst Ratings
Denali Therapeutics Is Maintained at Overweight by JP Morgan
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $24 to $87
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $87
Denali Therapeutics (DNLI) Gets a Buy From J.P. Morgan
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Denali Therapeutics Initiated at Outperform by Baird
Denali Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Inspire Medical Systems (INSP)
Denali Therapeutics Maintains Strong Buy Rating Amid Setbacks, Fueled by Promising BBB Platform
William Blair Initiates Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $35
Stifel Upgrades Denali Therapeutics(DNLI.US) to Buy Rating, Raises Target Price to $37